[go: up one dir, main page]

CL2008003305A1 - Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. - Google Patents

Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.

Info

Publication number
CL2008003305A1
CL2008003305A1 CL2008003305A CL2008003305A CL2008003305A1 CL 2008003305 A1 CL2008003305 A1 CL 2008003305A1 CL 2008003305 A CL2008003305 A CL 2008003305A CL 2008003305 A CL2008003305 A CL 2008003305A CL 2008003305 A1 CL2008003305 A1 CL 2008003305A1
Authority
CL
Chile
Prior art keywords
preparation process
excipients
cancer
optionally
injectable composition
Prior art date
Application number
CL2008003305A
Other languages
Spanish (es)
Inventor
Jain Rajesh
Singh Sukhjeet
Kumar Devrajan Sampath
Original Assignee
M/S Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M/S Panacea Biotec Ltd filed Critical M/S Panacea Biotec Ltd
Publication of CL2008003305A1 publication Critical patent/CL2008003305A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composición inyectable que comprende al menos un ingrediente seleccionado de antipsicóticos, inhibidores de aromatasa, bloqueante adrenérgico alfa-1, inhibidores de acetilcolinesterasa, al menos un polímero bioerosionable biocompatible y un solvente no tóxico; proceso de preparación.Injectable composition comprising at least one ingredient selected from antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocker, acetylcholinesterase inhibitors, at least one biocompatible bioerodible polymer and a non-toxic solvent; Preparation process.

CL2008003305A 2007-11-06 2008-11-06 Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. CL2008003305A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2321DE2007 2007-11-06

Publications (1)

Publication Number Publication Date
CL2008003305A1 true CL2008003305A1 (en) 2009-06-05

Family

ID=40626309

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003305A CL2008003305A1 (en) 2007-11-06 2008-11-06 Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.

Country Status (3)

Country Link
AR (1) AR070033A1 (en)
CL (1) CL2008003305A1 (en)
WO (1) WO2009060473A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
ES2390439B1 (en) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
HRP20211853T1 (en) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
PT2394664T (en) * 2010-05-31 2016-09-06 Farm Rovi Lab Sa Antipsychotic injectable depot composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
ES2675913T3 (en) * 2010-10-28 2018-07-13 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for transdermal administration
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
CN103491946B (en) 2010-12-29 2016-08-10 美蒂森 Biodegradable drug delivery compositions
DK2683364T3 (en) 2011-03-10 2017-02-27 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs.
PT2685979T (en) 2011-03-18 2016-12-02 Alkermes Pharma Ireland Ltd Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
CN103998026B (en) * 2011-10-24 2017-08-04 布雷本制药有限公司 Implantable drug delivery compositions and methods of treatment thereof
TWI583401B (en) 2011-10-24 2017-05-21 布雷本製藥股份有限公司 Implantable tizanidine compositions and methods of treatment thereof
JP6117811B2 (en) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド Formulations for treating diabetes
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
NZ630428A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160022571A1 (en) * 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
RU2688233C2 (en) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Aripiprazole preparations having high injection rates
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
CN104189954B (en) * 2014-09-19 2017-03-29 中国科学院长春应用化学研究所 A kind of in-situ solidifying tissue engineering bracket and preparation method thereof
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2017024027A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
DK3377041T3 (en) 2015-11-16 2023-12-18 Medincell S A METHOD FOR FRAGMENTATION AND/OR TARGETING OF PHARMACEUTICALLY ACTIVE INGREDIENTS TO SYNOVIAL TISSUE
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
KR102033686B1 (en) 2017-05-19 2019-10-18 보령제약 주식회사 Microneedle transdermal patch comprising donepezil
KR20240036128A (en) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. Precipitation resistant small molecule drug formulations
GB2568526A (en) * 2017-11-20 2019-05-22 Rebio Tech Oy Composition
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
PE20210047A1 (en) 2018-06-12 2021-01-08 Farm Rovi Lab Sa INJECTABLE COMPOSITION
WO2020065401A1 (en) * 2018-09-25 2020-04-02 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
US11911499B2 (en) * 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN113209370B (en) * 2020-01-21 2023-11-28 渼颜空间(河北)生物科技有限公司 Biodegradable injection filler, preparation method and application thereof
EP4216926A1 (en) * 2020-09-22 2023-08-02 Resurge Therapeutics, Inc. System and method for prostate treatment
WO2023278695A1 (en) * 2021-06-30 2023-01-05 The University Of North Carolina At Chapel Hill Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
WO2023116517A1 (en) * 2021-12-24 2023-06-29 四川科伦药物研究院有限公司 Continuous delivery preparation capable of being stably released and preparation method therefor
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
WO2025051281A1 (en) * 2023-09-08 2025-03-13 广州玻思韬控释药业有限公司 Brexpiprazole gel for injection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203157T1 (en) * 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
JP5244394B2 (en) * 2004-11-10 2013-07-24 トルマー セラピューティクス， インコーポレイテッド． Stabilized polymer delivery system
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
MX2009003735A (en) * 2006-10-05 2009-04-22 Panacea Biotec Ltd Injectable depot composition and its' process of preparation.

Also Published As

Publication number Publication date
WO2009060473A2 (en) 2009-05-14
AR070033A1 (en) 2010-03-10
WO2009060473A3 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
CL2008003305A1 (en) Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.
BRPI0916235A2 (en) compound, pharmaceutical composition, use of the compound or composition, and method for treating an hcv infected patient
ES2526606T3 (en) Solid pharmaceutical composition comprising amlodipine and losartan
ECSP088239A (en) COMPOSITION OF SUSTAINED DRUG RELEASE
AR093386A1 (en) COMPOSITION TO TREAT DIABETES OR DIABESITY INCLUDING AN OXINTOMODULIN ANALOG AND TREATMENT METHOD
CL2007003495A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED CONDENSED HETEROCICLES, INHIBITORS OF THE ACTIVITY OF THE AKT; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF CANCER.
AR054227A1 (en) COMPOSITION OF ACTIVE PRINCIPLES
CR11731A (en) COMPOSITIONS AND PROCEDURES FOR PREPARATION AND USE
PE20121555A1 (en) COMBINATION OF A POLYPLOID INDUCING AGENT AND A Bcl-2 INHIBITOR
AR047936A1 (en) MANIFULATION RESISTANT TRANSDERMIC DOSAGE FORM
CL2007001869A1 (en) COMPOUNDS DERIVED FROM BENCIMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES MODULATED WITH FXR AGONISTS, SUCH AS DISLIPIDEMIAS, DIABETES, CANCER, OSTEOPOROSIS AND E
CL2015001959A1 (en) (divisional application 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients
CL2009000393A1 (en) Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders.
CL2013001202A1 (en) Method for preventing plant diseases comprising applying an agent for soil treatment, where the agent comprises compounds derived from quinoline or its salts as active ingredient.
UY28438A1 (en) COMPOSITION OF A VEGF ANTAGONIST AND AN ANTIPROLIFERATIVE AGENT
UA109878C2 (en) Isoquinolinone derivatives, pharmaceutical composition based on them (variants), and method of treating diseases (variants)
AR083395A1 (en) NMU PEPTIDIC DERIVATIVE (NEUROMEDINA U) WITH ELEVATED ANORECTIC EFFECT
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
EP2490711A4 (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
CL2009001298A1 (en) Compounds derived from n-cyclohexyl-2-phenoxynicotinamide; pharmaceutical composition comprising them; pharmaceutical combination comprising them; and its use to treat a disease mediated by pde4.
AR072685A1 (en) TOPICAL COMPOSITION FOR THE TREATMENT OF ACTINIC KERATOSIS
CL2007003587A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE TO TREAT OR PREVENT INFECTION OF HEPATITIS C.
BR112012022337A2 (en) composition and method of preparation and use of effective amount
MX2008015775A (en) Compounds and compositions for treatment of cancer.